Asia Pacific Obesity Intervention Devices Market Size, Share & Industry Trends Analysis Report By End User (Hospitals and Clinics & Others), By Device (Gastric Bands, Gastric Balloon and Gastric Stimulation System), By Country and Growth Forecast, 2023 - 2029

The Asia Pacific Obesity Intervention Devices Market should witness market growth of 6.0% CAGR during the forecast period (2023-2029).

Obesity intervention devices are medical gadgets that are used to treat obesity and ameliorate or remit type 2 diabetes. During the forecast period, the rise in the prevalence of obesity and the number of market participants who produce obesity intervention devices are anticipated to boost market growth. Additionally, it is anticipated that an increase in the number of products offering obesity intervention devices and a boost in consumer awareness of these devices will fuel market growth during the forecast period.

Advancing technology that is relevant to intragastric balloon procedures is a major driver of market expansion. The intragastric balloon placement treatment has been shown to be highly effective in reducing body weight and alleviating the symptoms of concomitant diseases. Anatomically, this procedure is predicated on effects that take up more gastric space, which increase satiety and also have an impact on gut neuroendocrine signaling.

In Australia, 67% of adults (18 and older) were overweight or obese for the fiscal year 2017-18. Of this number, 36% were considered overweight but not obese, and 31% were considered obese. According to estimates, the specified demographic consists of about 12.5 million adults. Overweight and obesity were more common in men than in women, affecting 75% of men and 60% of women, respectively. among addition, 33% of men and 30% of women were obese, which was a larger prevalence among men. As seen by the fact that 41% of adults aged 65 to 74 were obese, compared to only 16% of adults aged 18 to 24, the prevalence of obesity tends to rise with age. This is expected to grow in the Asia-Pacific region.

The China market dominated the Asia Pacific Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $29.4 million by 2029. The Japan market is exhibiting a CAGR of 5.4% during (2023-2029). Additionally, The India market would experience a CAGR of 6.7% during (2023-2029).

Based on End-user, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.

Scope of the Study

By End-user

• Hospitals
• Clinics & Others

By Device

• Gastric Bands
• Gastric Balloon
• Gastric Stimulation System

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Johnson & Johnson
• Apollo Endosurgery, Inc. (Boston Scientific Corporation)
• ReShape Lifesciences, Inc.
• AbbVie, Inc.
• Allurion Technologies, Inc.
• Spatz FGIA, Inc
• Cousin Surgery
• A.M.I. GmbH
• ENDALIS
• GI Dynamics, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free